Population-Based Study of Risk of AKI with Levetiracetam

Kevin Yau, Jorge G. Burneo, Racquel Jandoc, Eric McArthur, Flory Tsobo Muanda, Chirag Parikh, Ron Wald, Matthew A. Weir, Amit X. Garg

Research output: Contribution to journalArticle

Abstract

BACKGROUND AND OBJECTIVES: Regulatory agencies warn about the risk of AKI with levetiracetam use on the basis of information from case reports. We conducted this study to determine whether new levetiracetam use versus nonuse is associated with a higher risk of AKI. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This was a population-based retrospective cohort study of adults with epilepsy in Ontario, Canada. Patients who received a new outpatient prescription for levetiracetam between January 1, 2004 and March 1, 2017 were matched to two nonusers on stage of CKD, recorded seizure in the prior 90 days, and logit of a propensity score for levetiracetam use. The primary outcome was a hospital encounter (emergency department visit or hospitalization) with AKI within 30 days of cohort entry. Secondary outcomes were AKI within 180 days and change in the concentration of serum creatinine. We assessed the primary outcome using health care diagnosis codes. We evaluated the change in the concentration of serum creatinine in a subpopulation with laboratory measurements. RESULTS: We matched 3980 levetiracetam users to 7960 nonusers (mean age 55 years, 51% women). Levetiracetam use was not significantly associated with a higher risk of AKI within 30 days (13 [0.33%] events in levetiracetam users and 21 [0.26%] events in nonusers [odds ratio, 1.24; 95% confidence interval, 0.62 to 2.47]). Similarly, there was no significant association with AKI within 180 days (odds ratio, 0.70; 95% confidence interval, 0.43 to 1.13). The change in the concentration of serum creatinine did not significantly differ between levetiracetam users and nonusers. CONCLUSIONS: In this population-based study levetiracetam use was not associated with a higher risk of AKI. PODCAST: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2018_12_11_Yau_Podcast.mp3.

Original languageEnglish (US)
Pages (from-to)17-26
Number of pages10
JournalClinical journal of the American Society of Nephrology : CJASN
Volume14
Issue number1
DOIs
StatePublished - Jan 7 2019

Fingerprint

etiracetam
Webcasts
Population
Creatinine
Serum
Odds Ratio
Confidence Intervals
Propensity Score

Keywords

  • Acute Kidney Injury
  • acute renal failure
  • creatinine
  • drug nephrotoxicity
  • Emergency Service
  • Epilepsy
  • etiracetam
  • evetiracetam
  • Hospital
  • hospitalization
  • interstitial, nephritis
  • Odds Ratio
  • Outpatients
  • Piracetam
  • Propensity Score
  • Renal, Insufficiency, Chronic
  • Retrospective Studies
  • Seizures

ASJC Scopus subject areas

  • Epidemiology
  • Critical Care and Intensive Care Medicine
  • Nephrology
  • Transplantation

Cite this

Population-Based Study of Risk of AKI with Levetiracetam. / Yau, Kevin; Burneo, Jorge G.; Jandoc, Racquel; McArthur, Eric; Muanda, Flory Tsobo; Parikh, Chirag; Wald, Ron; Weir, Matthew A.; Garg, Amit X.

In: Clinical journal of the American Society of Nephrology : CJASN, Vol. 14, No. 1, 07.01.2019, p. 17-26.

Research output: Contribution to journalArticle

Yau, K, Burneo, JG, Jandoc, R, McArthur, E, Muanda, FT, Parikh, C, Wald, R, Weir, MA & Garg, AX 2019, 'Population-Based Study of Risk of AKI with Levetiracetam', Clinical journal of the American Society of Nephrology : CJASN, vol. 14, no. 1, pp. 17-26. https://doi.org/10.2215/CJN.07490618
Yau, Kevin ; Burneo, Jorge G. ; Jandoc, Racquel ; McArthur, Eric ; Muanda, Flory Tsobo ; Parikh, Chirag ; Wald, Ron ; Weir, Matthew A. ; Garg, Amit X. / Population-Based Study of Risk of AKI with Levetiracetam. In: Clinical journal of the American Society of Nephrology : CJASN. 2019 ; Vol. 14, No. 1. pp. 17-26.
@article{54480bc4a8964e72abf18f718ad33e6e,
title = "Population-Based Study of Risk of AKI with Levetiracetam",
abstract = "BACKGROUND AND OBJECTIVES: Regulatory agencies warn about the risk of AKI with levetiracetam use on the basis of information from case reports. We conducted this study to determine whether new levetiracetam use versus nonuse is associated with a higher risk of AKI. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This was a population-based retrospective cohort study of adults with epilepsy in Ontario, Canada. Patients who received a new outpatient prescription for levetiracetam between January 1, 2004 and March 1, 2017 were matched to two nonusers on stage of CKD, recorded seizure in the prior 90 days, and logit of a propensity score for levetiracetam use. The primary outcome was a hospital encounter (emergency department visit or hospitalization) with AKI within 30 days of cohort entry. Secondary outcomes were AKI within 180 days and change in the concentration of serum creatinine. We assessed the primary outcome using health care diagnosis codes. We evaluated the change in the concentration of serum creatinine in a subpopulation with laboratory measurements. RESULTS: We matched 3980 levetiracetam users to 7960 nonusers (mean age 55 years, 51{\%} women). Levetiracetam use was not significantly associated with a higher risk of AKI within 30 days (13 [0.33{\%}] events in levetiracetam users and 21 [0.26{\%}] events in nonusers [odds ratio, 1.24; 95{\%} confidence interval, 0.62 to 2.47]). Similarly, there was no significant association with AKI within 180 days (odds ratio, 0.70; 95{\%} confidence interval, 0.43 to 1.13). The change in the concentration of serum creatinine did not significantly differ between levetiracetam users and nonusers. CONCLUSIONS: In this population-based study levetiracetam use was not associated with a higher risk of AKI. PODCAST: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2018_12_11_Yau_Podcast.mp3.",
keywords = "Acute Kidney Injury, acute renal failure, creatinine, drug nephrotoxicity, Emergency Service, Epilepsy, etiracetam, evetiracetam, Hospital, hospitalization, interstitial, nephritis, Odds Ratio, Outpatients, Piracetam, Propensity Score, Renal, Insufficiency, Chronic, Retrospective Studies, Seizures",
author = "Kevin Yau and Burneo, {Jorge G.} and Racquel Jandoc and Eric McArthur and Muanda, {Flory Tsobo} and Chirag Parikh and Ron Wald and Weir, {Matthew A.} and Garg, {Amit X.}",
year = "2019",
month = "1",
day = "7",
doi = "10.2215/CJN.07490618",
language = "English (US)",
volume = "14",
pages = "17--26",
journal = "Clinical journal of the American Society of Nephrology : CJASN",
issn = "1555-9041",
publisher = "American Society of Nephrology",
number = "1",

}

TY - JOUR

T1 - Population-Based Study of Risk of AKI with Levetiracetam

AU - Yau, Kevin

AU - Burneo, Jorge G.

AU - Jandoc, Racquel

AU - McArthur, Eric

AU - Muanda, Flory Tsobo

AU - Parikh, Chirag

AU - Wald, Ron

AU - Weir, Matthew A.

AU - Garg, Amit X.

PY - 2019/1/7

Y1 - 2019/1/7

N2 - BACKGROUND AND OBJECTIVES: Regulatory agencies warn about the risk of AKI with levetiracetam use on the basis of information from case reports. We conducted this study to determine whether new levetiracetam use versus nonuse is associated with a higher risk of AKI. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This was a population-based retrospective cohort study of adults with epilepsy in Ontario, Canada. Patients who received a new outpatient prescription for levetiracetam between January 1, 2004 and March 1, 2017 were matched to two nonusers on stage of CKD, recorded seizure in the prior 90 days, and logit of a propensity score for levetiracetam use. The primary outcome was a hospital encounter (emergency department visit or hospitalization) with AKI within 30 days of cohort entry. Secondary outcomes were AKI within 180 days and change in the concentration of serum creatinine. We assessed the primary outcome using health care diagnosis codes. We evaluated the change in the concentration of serum creatinine in a subpopulation with laboratory measurements. RESULTS: We matched 3980 levetiracetam users to 7960 nonusers (mean age 55 years, 51% women). Levetiracetam use was not significantly associated with a higher risk of AKI within 30 days (13 [0.33%] events in levetiracetam users and 21 [0.26%] events in nonusers [odds ratio, 1.24; 95% confidence interval, 0.62 to 2.47]). Similarly, there was no significant association with AKI within 180 days (odds ratio, 0.70; 95% confidence interval, 0.43 to 1.13). The change in the concentration of serum creatinine did not significantly differ between levetiracetam users and nonusers. CONCLUSIONS: In this population-based study levetiracetam use was not associated with a higher risk of AKI. PODCAST: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2018_12_11_Yau_Podcast.mp3.

AB - BACKGROUND AND OBJECTIVES: Regulatory agencies warn about the risk of AKI with levetiracetam use on the basis of information from case reports. We conducted this study to determine whether new levetiracetam use versus nonuse is associated with a higher risk of AKI. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This was a population-based retrospective cohort study of adults with epilepsy in Ontario, Canada. Patients who received a new outpatient prescription for levetiracetam between January 1, 2004 and March 1, 2017 were matched to two nonusers on stage of CKD, recorded seizure in the prior 90 days, and logit of a propensity score for levetiracetam use. The primary outcome was a hospital encounter (emergency department visit or hospitalization) with AKI within 30 days of cohort entry. Secondary outcomes were AKI within 180 days and change in the concentration of serum creatinine. We assessed the primary outcome using health care diagnosis codes. We evaluated the change in the concentration of serum creatinine in a subpopulation with laboratory measurements. RESULTS: We matched 3980 levetiracetam users to 7960 nonusers (mean age 55 years, 51% women). Levetiracetam use was not significantly associated with a higher risk of AKI within 30 days (13 [0.33%] events in levetiracetam users and 21 [0.26%] events in nonusers [odds ratio, 1.24; 95% confidence interval, 0.62 to 2.47]). Similarly, there was no significant association with AKI within 180 days (odds ratio, 0.70; 95% confidence interval, 0.43 to 1.13). The change in the concentration of serum creatinine did not significantly differ between levetiracetam users and nonusers. CONCLUSIONS: In this population-based study levetiracetam use was not associated with a higher risk of AKI. PODCAST: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2018_12_11_Yau_Podcast.mp3.

KW - Acute Kidney Injury

KW - acute renal failure

KW - creatinine

KW - drug nephrotoxicity

KW - Emergency Service

KW - Epilepsy

KW - etiracetam

KW - evetiracetam

KW - Hospital

KW - hospitalization

KW - interstitial, nephritis

KW - Odds Ratio

KW - Outpatients

KW - Piracetam

KW - Propensity Score

KW - Renal, Insufficiency, Chronic

KW - Retrospective Studies

KW - Seizures

UR - http://www.scopus.com/inward/record.url?scp=85059928437&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059928437&partnerID=8YFLogxK

U2 - 10.2215/CJN.07490618

DO - 10.2215/CJN.07490618

M3 - Article

C2 - 30538089

AN - SCOPUS:85059928437

VL - 14

SP - 17

EP - 26

JO - Clinical journal of the American Society of Nephrology : CJASN

JF - Clinical journal of the American Society of Nephrology : CJASN

SN - 1555-9041

IS - 1

ER -